Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service superficial venous ablation cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (235 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 30 | 3,241 | 42% |
| 2020 | 24 | 3,222 | 45% |
| 2021 | 24 | 2,643 | 48% |
| 2022 | 23 | 2,150 | 51% |
| 2023 | 18 | 2,048 | 54% |
| 2024 | 19 | 2,060 | 56% |
| 2025 from claims | – | 2,137 1,961–2,261 | 57% |
| 2026 forecast | – | 2,172 1,911–2,506 | 57% |
| 2027 forecast | – | 2,197 1,878–2,618 | 58% |
| 2028 forecast | – | 2,223 1,855–2,722 | 58% |
| 2029 forecast | – | 2,249 1,837–2,820 | 59% |
| 2030 forecast | – | 2,274 1,822–2,914 | 60% |
Radiofrequency, laser, and adhesive ablation of the saphenous veins; office and vein-clinic heavy. Professional codes (what the surgeon bills): CPT 36475, 36478, 36482.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 88% of the cases CMS names in Nevada; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 1% hospital outpatient, 99% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 224 | 22,010−1.1%/yr | −1.1%/yr | 6.3 | 98% | 24,700 in 2030+2%/yr |
| Arizona | 94 | 10,087−0.8%/yr | −0.8%/yr | 13.0 | 100% | 10,200 in 2030+0.2%/yr |
| Colorado | 41 | 3,790+0.3%/yr | +0.3%/yr | 7.4 | 99% | 5,330 in 2030+5.9%/yr |
| Utah | 15 | 962−9.3%/yr | −9.3%/yr | 4.2 | 92% | 750 in 2030−4%/yr |
| Oregon | 18 | 938−1%/yr | −1%/yr | 2.1 | 96% | 960 in 2030+0.4%/yr |
| New Mexico | 8 | 925−4.6%/yr | −4.6%/yr | 3.8 | 96% | 850 in 2030−1.4%/yr |
| Washington | 7 | 779−7.1%/yr | −7.1%/yr | 1.0 | 83% | 860 in 2030+1.7%/yr |
| Montana | 6 | 568−13%/yr | −13%/yr | 2.9 | 94% | 490 in 2030−2.4%/yr |
| Hawaii | 4 | 442+29%/yr | +29%/yr | 3.3 | 100% | 390 in 2030−2.2%/yr |
| Wyoming | 4 | 425−3.4%/yr | −3.4%/yr | 3.8 | 100% | 570 in 2030+4.9%/yr |
| Idaho | 7 | 286−4.7%/yr | −4.7%/yr | 1.3 | 72% | 300 in 2030+1.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 20 | 2,124−8.8%/yr | −8.8%/yr | 7.71.6× | 96% | 2,190 in 2030+0.5%/yr |
| Peripheral arterial intervention | 9 | 1,215−6.2%/yr | −6.2%/yr | 4.00.8× | 73% | 1,790 in 2030+6.7%/yr |
| Thrombectomy, IVC filters & venous stents | 3 | 412−4.7%/yr | −4.7%/yr | 1.41.2× | 0% | 540 in 2030+4.7%/yr |
| Carotid revascularization | 11 | 315−0.4%/yr | −0.4%/yr | 1.11.3× | 0% | 610 in 2030+11%/yr |
| Aortic endografts (EVAR/TEVAR) | 0 | 117−8%/yr | −8%/yr | 0.41.3× | 0% | 100 in 2030−2.4%/yr |
Superficial venous ablation in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
Medtronic leads with 89% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 3 companies reported engagement with Nevada’s surgeons worth $8,027 in consulting, speaking, meals and travel tied to these products, about $422 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.